All In Biotech

NDA 213312 · Aadi

Fyarro

Sirolimus · Intravenous · mTOR Inhibitor Immunosuppressant; Kinase Inhibitor

Breakthrough therapyPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Nov 22, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,853

224 Phase 3, 143 recruiting

FAERS reports

13,519

11,687 serious, 2,180 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 9, 2026.

FYARRO ® is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). ( 1 )

Mechanism: Sirolimus in FYARRO is an inhibitor of mechanistic target of rapamycin kinase (mTOR, previously known as mammalian target of rapamycin). mTOR, a serine threonine kinase, is downstream of the PI3K/AKT pathway, controls key cellular processes such as cell survival, growth, and proliferation, and is commonly dysregulated in several human cancers. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus-FKBP-12 complex binds to and inhibits activation of the mechanistic target of rapamycin complex 1 (mTORC1)....

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 22, 2021 Original approval · Type 5 - New Formulation or New Manufacturer · priority review Breakthrough therapyOrphanLabelLetterReview
1 products under this application
  • FYARRO · SIROLIMUS 100MG/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Sirolimus" as an intervention, any sponsor and status, largest first.

All 1,853 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,076
  • drug ineffective1,140
  • product use in unapproved indication786
  • pyrexia533
  • diarrhoea529
  • pneumonia500
  • drug interaction450
  • acute kidney injury444
  • thrombotic microangiopathy386
  • transplant rejection384
  • cytomegalovirus infection355
  • condition aggravated318

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200441
200553
200651
2007232
2008194
2009294
2010152
2011253
2012231
2013204
2014239
2015315
2016425
2017598
2018845
2019990
20201,021
20211,054
20221,240
20231,139
20241,444
20251,502
20261,002

Recalls

1 FDA enforcement reports for this application.

  • Oct 13, 2022 · Class III · Terminated

    Failed Stability Specifications

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Fyarro (Sirolimus Protein-Bound) · HCPCS J9331

2024 spending

$7.7M

Beneficiaries

34

378 claims

Per beneficiary

$225,713

2024 ASP limit $93.85 per unit

View as table
YearSpending
2020$0
2021$0
2022$1,762,281
2023$8,104,505
2024$7,674,229

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,786 on PubMed

Sponsor: Aadi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.